Why Atara’s FDA Rejection Does Not Apply to uniQure — and Why It May Actually Strengthen the AMT-130 Thesis

Don't miss the forest from the trees

*Quick update note on ATRA and what this means for QURE (and others in the space). No change to PT.*

Today, Atara Biotherapeutics (NASDAQ: ATRA) was rejected by the FDA. Almost immediately, the market reaction has been to generalize this outcome across the high-risk biotech complex, including uniQure (NASDAQ: QURE). This reflex is understandable—but wrong.